Shire strikes deal with Servier to sell its cancer unit for USD 2.4B
Category: #health  By Dhananjay Punekar  Date: 2018-04-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

Shire strikes deal with Servier to sell its cancer unit for USD 2.4B

Shire Plc, a global specialty biopharma firm headquartered in Ireland, has apparently entered into an agreement with a France based pharmaceutical company, Servier Laboratories. The agreement validates the sale of Shire’s oncology business for USD 2.4 billion in currency to Servier.

Incidentally, last month, Takeda had been considering the acquisition bid for Shire, citing oncology as one of the common threads for associating itself with the Irish firm. The key officials of Takeda were of the view that the partnership between the two firms will strengthen the Japanese company’s therapeutic business including neuroscience, oncology, and gastroenterology.

The company also stated that adding Shire’s rare disease contract will further benefit Takeda’s business portfolio. However, the Japan-based firm did not make any offer to Shire, nor had it specified any intent of buying out the Irish firm. Post the declaration of selling its oncology business, the stock price of Ireland-based biopharma firm jumped 1.6% and closed at £36.63, as per The Financial Times.

Reportedly, Shire Plc states that the proceeds from the oncology business sale will help it to “raise optionality”. It has also been speculated that the company plans to return the cash from the sale to the investors through buyback.

For the record, in December last year, the board of directors of Shire had been looking out for various alternatives for selling its cancer treatment business. However, the process of sale commenced in January this year with the firm identifying numerous potential buyers across Japan, the U.S., and Europe.

Olivier Laureau, the President of Servier Labs, has proclaimed that the acquisition of the cancer therapy business will help the firm in making its presence felt across the U.S. pharmaceutical industry. He further added that this strategic business decision may also sufficiently enhance the product portfolio of Servier and will help the company make cancer treatment available to a large patient base across the globe.



About Author

Dhananjay Punekar

Email: [email protected]   

Dhananjay Punekar

Dhananjay Punekar presently develops content for a slew of portals, including Market Size Forecasters and Algosonline. A post graduate in mathematics and business administration, he worked in Infosys BPO Limited prior to switching his professional genre. As a content wr...

Read More

More News By Dhananjay Punekar

AstraZeneca gets import & marketing approval for Durvalumab in India
AstraZeneca gets import & marketing approval for Durvalumab in India
By Dhananjay Punekar

AstraZeneca Pharma India, a division of pharma & biopharma giant AstraZeneca plc, has received a green signal from the Indian drug regulating agency DCGI (Drug Controller General of India) for its drug Durvalumab c...

BP exits deal with Woolworths, retail firm looks out for alternatives
BP exits deal with Woolworths, retail firm looks out for alternatives
By Dhananjay Punekar

BP Plc, a UK based oil & gas firm, has decided to terminate its USD 1.8 billion acquisition deal with Australian retail giant Woolworths. For the record, the British oil & gas company had signed a pact to purch...

Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
Sarepta obtains positive results on DMD therapy, shares skyrocket 50%
By Dhananjay Punekar

The shares of Sarepta Therapeutics Inc., a medical research & drug development firm, climbed up by 50% after the firm released initial results derived from clinical treatment on patients suffering from Duchenne mus...